Background: Targeted medical therapy and balloon pulmonary angioplasty (BPA) entered the field of chronic thromboembolic pulmonary hypertension (CTEPH) treatment in the early 2010's. Multimodal therapy is emerging as the new gold standard for CTEPH management. Whether this change of paradigm impacted early outcomes of pulmonary endarterectomy (PEA) remains unknown. Our aim is to report our surgical experience in the era of CTEPH multimodal management. Methods: Patients who underwent PEA between 2016 and 2020 were included in the study. Early outcomes were described and compared between three groups of patients: PEA alone, PEA after targeted medical therapy induction and PEA after BPA. Results: A total of 418 patients, 225 males and 193 females, with a mean age of 59±14 years were included in the study. 336 patients underwent PEA alone, 69 after medical targeted therapy induction and 13 after unilateral BPA. Baseline preoperative pulmonary vascular resistance [4.99 (IQR, 1.71-8.48), 6.21 (IQR, 4.37-8.1), 5.03 (IQR, 4.44-7.19) wood units (WU), P=0.230, respectively] and PEA effectiveness [% decrease mean pulmonary artery pressure (mPAP), 24 (IQR, 7-42), 25 (IQR, 7-35), 23 (IQR, 3-29), P=0.580] did not differ between groups. Compared to PEA alone and PEA+BPA, the medical therapy induction group represented the most challenging group with higher baseline mPAP (45±10 vs. 42±11 and 43±11 mmHg, P=0.047), longer circulatory arrest time (30.1±15 vs. 26.6±10 and 19.6±6 min, P=0.005), higher post-PEA extracorporeal membrane oxygenation use (20.6% vs. 8.7 and 9.1%, P=0.004), higher duration on mechanical ventilation [4 (IQR, 1-12) vs. 1 (IQR, 0.5-5) and 2 (IQR, 1-3) days, P=0.005], higher complication rate (85.5% vs. 74.6% and 76.9%, P=0.052) and higher 90-day mortality (13% vs. 3.9% and 0%, P=0.002). Compared to PEA and PEA+ medical therapy induction groups, patients in the BPA induction group were older [72 (IQR, 62-76) vs. 60 (IQR, 48-69) and 62 (IQR, 52-72) years, P=0.005], and underwent shorter cardiopulmonary bypass (191.9±47.9 vs. 222±107.2 and 236.8±46.4 min, P<0.001), aortic cross clamping (54.8±21 vs. 82.7±31.4 and 80.1±32.9 min, P=0.002) and circulatory arrest time (19.6±6.2 vs. 26.6±10.8 and 30.1±15.1 min, P=0.008). Conclusions: Multimodal therapy approach to CTEPH patients did not affect effectiveness of PEA. Medical therapy and BPA could act in synergy with surgery to treat more challenging patients. 2022 Annals of Cardiothoracic Surgery. All rights reserved.
Background: Targeted medical therapy and balloon pulmonary angioplasty (BPA) entered the field of chronic thromboembolic pulmonary hypertension (CTEPH) treatment in the early 2010's. Multimodal therapy is emerging as the new gold standard for CTEPH management. Whether this change of paradigm impacted early outcomes of pulmonary endarterectomy (PEA) remains unknown. Our aim is to report our surgical experience in the era of CTEPH multimodal management. Methods: Patients who underwent PEA between 2016 and 2020 were included in the study. Early outcomes were described and compared between three groups of patients: PEA alone, PEA after targeted medical therapy induction and PEA after BPA. Results: A total of 418 patients, 225 males and 193 females, with a mean age of 59±14 years were included in the study. 336 patients underwent PEA alone, 69 after medical targeted therapy induction and 13 after unilateral BPA. Baseline preoperative pulmonary vascular resistance [4.99 (IQR, 1.71-8.48), 6.21 (IQR, 4.37-8.1), 5.03 (IQR, 4.44-7.19) wood units (WU), P=0.230, respectively] and PEA effectiveness [% decrease mean pulmonary artery pressure (mPAP), 24 (IQR, 7-42), 25 (IQR, 7-35), 23 (IQR, 3-29), P=0.580] did not differ between groups. Compared to PEA alone and PEA+BPA, the medical therapy induction group represented the most challenging group with higher baseline mPAP (45±10 vs. 42±11 and 43±11 mmHg, P=0.047), longer circulatory arrest time (30.1±15 vs. 26.6±10 and 19.6±6 min, P=0.005), higher post-PEA extracorporeal membrane oxygenation use (20.6% vs. 8.7 and 9.1%, P=0.004), higher duration on mechanical ventilation [4 (IQR, 1-12) vs. 1 (IQR, 0.5-5) and 2 (IQR, 1-3) days, P=0.005], higher complication rate (85.5% vs. 74.6% and 76.9%, P=0.052) and higher 90-day mortality (13% vs. 3.9% and 0%, P=0.002). Compared to PEA and PEA+ medical therapy induction groups, patients in the BPA induction group were older [72 (IQR, 62-76) vs. 60 (IQR, 48-69) and 62 (IQR, 52-72) years, P=0.005], and underwent shorter cardiopulmonary bypass (191.9±47.9 vs. 222±107.2 and 236.8±46.4 min, P<0.001), aortic cross clamping (54.8±21 vs. 82.7±31.4 and 80.1±32.9 min, P=0.002) and circulatory arrest time (19.6±6.2 vs. 26.6±10.8 and 30.1±15.1 min, P=0.008). Conclusions: Multimodal therapy approach to CTEPH patients did not affect effectiveness of PEA. Medical therapy and BPA could act in synergy with surgery to treat more challenging patients. 2022 Annals of Cardiothoracic Surgery. All rights reserved.
Authors: Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin Journal: N Engl J Med Date: 2013-07-25 Impact factor: 91.245
Authors: P Dartevelle; E Fadel; S Mussot; A Chapelier; P Hervé; M de Perrot; J Cerrina; F L Ladurie; D Lehouerou; M Humbert; O Sitbon; G Simonneau Journal: Eur Respir J Date: 2004-04 Impact factor: 16.671
Authors: Christoph B Wiedenroth; Christoph Liebetrau; Andreas Breithecker; Stefan Guth; Hans-Jürgen F Lautze; Erik Ortmann; Matthias Arlt; Gabriele A Krombach; Dirk Bandorski; Christian W Hamm; Helge Möllmann; Eckhard Mayer Journal: J Heart Lung Transplant Date: 2015-10-30 Impact factor: 10.247
Authors: Laura Donahoe; John Granton; Karen McRae; John Thenganatt; Jacov Moric; Shaf Keshavjee; Marc de Perrot Journal: Interact Cardiovasc Thorac Surg Date: 2016-03-30
Authors: Marion Delcroix; Irene Lang; Joanna Pepke-Zaba; Pavel Jansa; Andrea M D'Armini; Repke Snijder; Paul Bresser; Adam Torbicki; Sören Mellemkjaer; Jerzy Lewczuk; Iveta Simkova; Joan A Barberà; Marc de Perrot; Marius M Hoeper; Sean Gaine; Rudolf Speich; Miguel A Gomez-Sanchez; Gabor Kovacs; Xavier Jaïs; David Ambroz; Carmen Treacy; Marco Morsolini; David Jenkins; Jaroslav Lindner; Philippe Dartevelle; Eckhard Mayer; Gérald Simonneau Journal: Circulation Date: 2016-01-29 Impact factor: 29.690
Authors: Marc de Perrot; Deepa Gopalan; David Jenkins; Irene M Lang; Elie Fadel; Marion Delcroix; Raymond Benza; Gustavo A Heresi; Manreet Kanwar; John T Granton; Micheal McInnis; Frederikus A Klok; Kim M Kerr; Joanna Pepke-Zaba; Mark Toshner; Anastasia Bykova; Andrea M D' Armini; Ivan M Robbins; Michael Madani; David McGiffin; Christoph B Wiedenroth; Sebastian Mafeld; Isabelle Opitz; Olaf Mercier; Patricia A Uber; Robert P Frantz; William R Auger Journal: J Heart Lung Transplant Date: 2021-08-03 Impact factor: 10.247